Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington’s disease. Further, ALN-HTT was well tolerated in … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards